Clinical Trial Update: Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 [Phase 2]

View source ↗

Summary

Phase 2 trial update for dovitinib in gastric cancer with FGFR2 amplification (GASDOVI-1) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED